Authors

Latest:

Dr. Hays on Targeting Mutations in Gynecologic Cancers

John Hays, MD, assistant professor of Internal Medicine, Ohio State University Comprehensive Cancer Center, discusses how researchers are actively exploring how to target rarer mutations in patients with a variety of gynecologic cancers.

John Hays, MD, PhD

Latest:

Dr Hays on the Evolution of Later-line Treatment Options in Refractory mCRC

John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.

John Heymach, MD, PhD

Latest:

Dr Heymach on Updated AEGEAN Data in Resectable NSCLC

John V. Heymach, MD, PhD, discusses updated outcomes from the AEGEAN trial of perioperative durvalumab vs placebo in resectable non–small cell lung cancer.

John Heymach, MD, PhD, MD Anderson Cancer Center

Latest:

AEGEAN: A Phase 3 Trial of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab in Patients with Resectable NSCLC

Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.

John Kuruvilla, MD, FRCPC

Latest:

Dr. Kuruvilla on the Safety of Pembrolizumab in Classical Hodgkin Lymphoma

John Kuruvilla, MD, FRCPC, discusses the safety of pembrolizumab (Keytruda) versus brentuximab vedotin in classical Hodgkin lymphoma.

John L. Marshall, MD

Latest:

Dr Marshall on Updates in CRC Following the 2024 ASCO Annual Meeting

John L. Marshall, MD, discuss updates in colorectal cancer management at the 2024 ASCO Annual Meeting.

John L. Marshall, MD, Ge

John L. Marshall, MD, Georgetown

John L. Marshall, MD, Georgetown University

Latest:

Advanced Cholangiocarcinoma: Molecular Testing

Experts who treat patients with GI cancers, such as cholangiocarcinoma, emphasize the need for more standardized approaches to molecular testing.

John L. Marshall, MD, Georgetown University Hospital

John L. Marshall, MD, Georgetown University Medical Center

John L. Marshall, MD, MedStar Georgetown University Hospital

Latest:

Novel Approaches Under Study for Metastatic CRC

John L. Marshall, MD; Marwan G. Fakih, MD; and Joleen M. Hubbard, MD, highlight novel strategies in the metastatic colorectal cancer pipeline that look exciting and consider their integration into future clinical practice.

John L. Marshall, MD, The Ruesch Center for the Cure of GI Cancers

Latest:

Perspectives on Treating CCA Moving Forward

A panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.

John Leonard, MD

Latest:

Dr. Leonard on the Future of PI3K Inhibitors in Follicular Lymphoma

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.

John Leonard, MD, New York-Presbyterian Hospital

John Leonard, MD, New York-Presbyterian/Weill Cornell Center for Lymphoma

John Leonard, MD, Weill Cornell Medical College

John Lynn

Latest:

Does Your EHR Consultant Have Your Best Interests in Mind?

When selecting an EHR for your practice, using an EHR consultant can save you time, money, and headaches.

John M. Burke, MD

Latest:

Dr Burke on the Assessment of Barriers to Initiating Venetoclax-Based Regimens for CLL

John M. Burke, MD, discusses the barriers to initiating venetoclax-based regimens for chronic lymphocytic leukemia.

John M. Kirkwood, MD

Latest:

Dr Kirkwood on the Evolving Treatment of Resected Melanoma

John M. Kirkwood, MD, discusses the significance of the FDA approval of adjuvant nivolumab for patients with resected stage IIB or IIC melanoma.